Currently, the IBS treatment market is naïve and underpenetrated, with only 4 products indicated for IBS in the 7MM.
Managed care and hospital decision-makers are in a key position to “move the needle” at the system level on improving adult immunization coverage rates in the United States.
More than one-third of reproductive-aged women enrolled in Medicaid, and more than a quarter of those with private insurance, filled a prescription for an opioid pain medication each year during 2008 to 2012, according to a recent...
The number of antibiotic-resistant strains continues to rise rapidly. Statistics from the Centers for Disease Control and Prevention (CDC) and the Infectious Diseases Society of America (IDSA) point to alarming trends that are...
It is with great excitement that we unveil our network-wide redesign. Please read further to learn more about a few of our new features, and browse around to explore the new site!

FDA APPROVALS
FDA approves new administration ...

FDA has approved a new administration option for ticagrelor (Brilinta, AstraZeneca) in acute coronary syndrome patients.

FDA approves label update for Zytiga
FDA approves DTaP-IPV combo vaccine ...
Faster FDA approvals lead to cancer ...

CLINICAL
FDA approves new administration ...

FDA has approved a new administration option for ticagrelor (Brilinta, AstraZeneca) in acute coronary syndrome patients.

BioCryst receives $12 million to ...
FDA approves label update for Zytiga
New insulin may get speedy FDA approval

DRUGS IN PERSPECTIVE
Drugs in Perspective: Opdivo (nivolumab)

On December 22, 2014, Opdivo (nivolumab) was approved by FDA with a breakthrough therapy designation. Nivolumab is the ...

Drugs in Perspective: Myalept ...
Drugs in Perspective: Otezla ...
Drugs in Perspective: Zykadia ...

Latest Tweets Follow